Elsevier

Experimental Eye Research

Volume 75, Issue 6, December 2002, Pages 625-634
Experimental Eye Research

Regular Article
Inhibition of Corneal Neovascularization by Recombinant Adenovirus Mediated Antisense VEGF RNA

https://doi.org/10.1006/exer.2002.2075Get rights and content

Abstract

The expression of vascular endothelial growth factor has been strongly implicated in the pathogenesis of conditions leading to inappropriate blood vessel growth in the eye. As such, vascular endothelial growth factor is an attractive target for anti-angiogenic therapies designed to treat neovascular eye diseases. Onesuch therapy, antisense gene therapy, is a technique based on the ability of single-stranded DNA or RNA sequences to alter the expression of targeted genes. Recombinant adenoviruses have demonstrated efficient ocular cell transduction with a high level of transgene production. Cauterization of the normally avascular rat cornea results in a strong neovascular response, making it an ideal animal model for the testing of anti-angiogenic therapies. In this study, a recombinant adenovirus system was assessed for the ability to express biologically relevant antisense RNA to reduce vascular endothelial growth factor expression in a rat model of corneal neovascularization. Recombinant adenovirus constructs expressing short and long antisense and sense vascular endothelial growth factor cDNA, under the control of cytomegalovirus major immediate early promoter or the RNA polymerase III promoter, VA1, were constructed. The expression of short and long antisense RNAs was demonstrated by Northern blot hybridization. All constructs were capable of producing RNA, and the highest level of antisense RNA production was detected in retinal pigment epithelial cells which had been transduced with the longer antisense cDNA construct under the control of the VA1 promoter. This construct was also the most efficient in reducing in vitro vascular endothelial growth factor production (P < 0.05) and human endothelial cell proliferation. This construct was subsequently injected into rat eyes 24 hr prior to cauterization of the cornea and antisense vascular endothelial growth factor expression was demonstrated by in situ hybridization. The resulting neovascular response was clearly inhibited at 4, 7 and 14 days post-cautery, compared to the control injections which demonstrated an intense neovascular response. Only one out of six eyes injected with the long antisense cDNA construct under the control of the VA1 promoter demonstrated any vascular response to cautery. The reduction in the neovascular response was correlated, with significantly lower amounts of vascular endothelial growth factor protein in the corneas (P = 0.006). These observations suggest that the specific down-regulation of vascular endothelial growth factor production is sufficient to reduce the corneal neovascular response and that recombinant adenovirus might be a useful vehicle to produce antisense RNA in situ to down-regulate ocular gene expression.

References (46)

  • B. Belletti et al.

    Modulation of invivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene

    Oncogene

    (1999)
  • M. Boulton et al.

    VEGF localisation in diabetic retinopathy

    Br. J. Ophthalmol

    (1998)
  • L. Cagnon et al.

    Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule

    J. Acquir. Immune Defic. Syndr. Hum. Retrovirol

    (1995)
  • S.-Y. Cheng et al.

    Suppression of glioblastoma angiogenicity andtumorigenicity by inhibition of endogenous expressionof vascular endothelial growth factor

    Proc. Nat.. Acad. Sci. U.S.A

    (1996)
  • M. Clauss et al.

    Vascular permeability factor: atumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration

    J. Exp. Med

    (1990)
  • G.J. Clesham et al.

    Enhancer stimulation unmasks latent gene transfer after adenovirus-mediated gene delivery into human vascular smooth muscle cells

    Circ. Res

    (1996)
  • J.L. Edelman et al.

    Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea

    Invest. Ophthalmol. Vis. Sci

    (1999)
  • P.D. Good et al.

    Expression of small, therapeutic RNAs in human cell nuclei

    Gene Ther

    (1997)
  • F. Graham et al.

    Manipulation of adenovirus vectors

    Methods in Molecular Biology, Gene Transfer and Expression Protocols

    (1991)
  • Z.S. Guo et al.

    Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer

    Gene Ther

    (1996)
  • L. Hoffman et al.

    Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery

    Invest. Ophthalmol. Vis. Sci

    (1997)
  • K.A. Houck et al.

    The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA

    Molec. Endocrinol

    (1991)
  • Cited by (70)

    • VEGF-targeted scFv inhibits corneal neovascularization via STAT3 pathway in alkali burn model

      2023, Colloids and Surfaces A: Physicochemical and Engineering Aspects
      Citation Excerpt :

      VEGF is a key target for blocking the cascade of neovascular formation. By binding to VEGFR, it induces a signaling cascade that promotes endothelial cell growth, survival, migration, and differentiation [24]. To date, a large number of researches have revealed that the VEGF family is considerably enhanced in inflammation and blood vessels in both human and animal models, involved in neovascularization development [1].

    • RNA-targeting strategies as a platform for ocular gene therapy

      2023, Progress in Retinal and Eye Research
    • Gene-based antiangiogenic applications for corneal neovascularization

      2018, Survey of Ophthalmology
      Citation Excerpt :

      Subconjunctival injection of synthetic siRNAs was able to silence VEGF-A sequences and inhibit mouse corneal angiogenesis induced by alkali burn, showing 2.34 mm2 less neovascularized area than the uninjected controls.310 Utilizing a similar approach, shRNA or antisense oligonucleotide-mediated silencing of VEGF-A also effectively suppressed corneal neovascularization in murine models.161,229 Although clinical trials of VEGF siRNA for corneal neovascularization have not been reported, this approach is currently undergoing clinical evaluation to treat age-related macular degeneration.132,198,199

    View all citing articles on Scopus
    f1

    *Please note the first and second authors have contributed equally to this paper.

    f2

    Address correspondence to: P. E. Rakoczy, Lions Eye Institute, 2Verdun St, Nedlands WA 6009, Australia. E-mail: rakoczy@ cyllene.uwa.edu.au

    View full text